

# Special Issue

## Surgery for Colorectal Cancer

### Message from the Guest Editors

Colorectal cancer (CRC) commonly metastasizes; approximately 50% of patients with CRC develop metastasis. Despite advancements in therapy and surgery, the 5-year overall survival rate of patients with CRC metastasis is below 40%. This Special Issue welcomes contributions in the form of original research papers and reviews that cover the following themes:

- Novel therapeutic approaches targeting metastasis from CRC;
- Preclinical experimental models studying metastasis from CRC;
- Translational studies related to metastasis from CRC;
- Novel methodological approaches and advances in software tools improving the phenotypic and molecular characterization of metastasis from CRC;
- Methods to improve education and information to reduce socio-economic disparities in colon-rectal cancer screening;
- Clinical and oncologic outcomes after robotic surgery for colon-rectal cancer;
- Clinical and oncologic outcomes for minimally invasive surgery for localized colon and rectal cancer.

### Guest Editors

Prof. Dr. Antonio V. Sterpetti

Department of Surgery "Pietro Valdoni", University of Rome, 00161 Rome, Italy

Prof. Dr. Raimondo Gabriele

Department of Surgery "Pietro Valdoni", University of Rome, 00161 Rome, Italy

### Deadline for manuscript submissions

31 December 2025



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/205275](https://mdpi.com/si/205275)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)